Phase II Study of Ponatinib in Advanced Gastrointestinal Stromal Tumors: Efficacy, Safety, and Impact of Liquid Biopsy and Other Biomarkers.
Suzanne GeorgeMargaret von MehrenJonathan A FletcherJichao SunSen ZhangJustin R PritchardJohn Graeme HodgsonDavid KersteinVictor M RiveraFrank G HaluskaMichael C HeinrichPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Ponatinib demonstrated activity in advanced GIST, particularly in KIT ex11-positive disease. ctDNA analysis confirmed heterogeneous resistance mutations in TKI-pretreated advanced GIST. Safety was consistent with previous studies.
Keyphrases
- phase ii study
- chronic myeloid leukemia
- open label
- locally advanced
- tyrosine kinase
- squamous cell carcinoma
- randomized controlled trial
- ionic liquid
- clinical trial
- advanced non small cell lung cancer
- rectal cancer
- case control
- placebo controlled
- fine needle aspiration
- epidermal growth factor receptor
- data analysis